NAPLES, Fla., Oct. 26, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for…
NAPLES, Fla., Oct. 7, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for…
– Paving the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress – NAPLES, Fla., Oct. 5, 2021 — Enveric Biosciences (NASDAQ: ENVB)…
NAPLES, Fla., Sept. 20, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the…
Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress NAPLES, Fla., Sept. 17, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),…
NAPLES, Fla., Sept. 9, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
Company has also released its second quarter and first half financial results for the period ended June 30, 2021 NAPLES, Fla., Aug. 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric”…
Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
NAPLES, Fla., June 3, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer…
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with…